Archive · 13 Jan 2026
Biocon Gets USFDA Approval for Everolimus Tablets
Biocon, a big pharmaceutical company, got approval from the US FDA for a new medicine called Everolimus Tablets.
These tablets come in different strengths and are used to treat a condition called Tuberous Sclerosis Complex (TSC) in both adults and children.
The approval is expected to help Biocon expand its range of medicines.
However, after the announcement, the company's stock price went down slightly.
The stock is currently trading at Rs 376, which is a bit lower than before.
The company's promoters own about 48.27% of the company, which is a bit less than before.
The stock has been a bit volatile lately, but it's still above some of its long-term averages.
Biocon Pharma Ltd received USFDA approval for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg, and 5 mg strengths.
The tablets are indicated for treating Tuberous Sclerosis Complex (TSC) and associated conditions in adult and pediatric patients.
The approval is expected to strengthen Biocon's portfolio of vertically integrated drug products.
Despite the approval, Biocon's stock price decreased by 0.96% to Rs 376.
Promoters held a 48.27% stake in Biocon as of December 2025, down from the previous quarter.
- Who
- Biocon Ltd and its subsidiary Biocon Pharma Ltd
- What
- Received USFDA approval for Everolimus Tablets for Oral Suspension
- When
- Announced on Monday
- Where
- United States
- Why
- To strengthen its portfolio of vertically integrated drug products
- Company
- Biocon Ltd
- Subsidiary
- Biocon Pharma Ltd
- Approval Received
- USFDA ANDA approval for Everolimus Tablets for Oral Suspension
- Strengths Approved
- 2 mg, 3 mg, and 5 mg
- Indications
- Treatment of Tuberous Sclerosis Complex (TSC) and associated conditions
- Stock Price
- Rs 376 (down 0.96%)
- Promoter Stake
- 48.27% (as of December 2025)
